(MENAFN - ProactiveInvestors) Imugene () is preparing to initiate this year the clinical program for its Her-Vaxx peptide vaccine a B-cell based immunotherapy for HER-2 positive gastric & breast cancer.
Her-Vaxx has potential to improve upon Roche’s blockbuster Herceptin drug that generated annualised sales of $6.9 billion and targets the same biomarker.
It was developed by one of Europe’s leading cancer institutes with about $10 million already invested in the technology.
Managing director Charles Walker outlined these points and many others at the February 2015 Proactive Investors Melbourne / Sydney Luncheons.
The full presentation can be ACCESSED HERE.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia UK North America and Hong Kong / China.